Syndax Announces Participation at Citi's Biopharma Virtual Co-Panel Day

Rhea-AI Summary

Syndax Pharmaceuticals, a clinical-stage biopharmaceutical firm focused on cancer therapies, announced CEO Michael A. Metzger's participation in a targeted oncology panel at Citi's Biopharma Virtual Co-Panel Day on May 18, 2022, at 1:30 p.m. ET. The event will highlight the company's innovative drug pipeline, including revumenib and axatilimab, which are currently in pivotal trials. A live webcast of the panel will be available on their website, along with a replay for limited access.

Positive

• CEO Michael A. Metzger will participate in a significant oncology panel at a prominent industry event.
• Syndax's pipeline includes promising candidates like revumenib and axatilimab, which are in pivotal trials.

Negative

• None.

WALTHAM, Mass., May 11, 2022 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer of Syndax, will participate in a panel discussion on targeted oncology at Citi's Biopharma Virtual Co-Panel Day on Wednesday, May 18, 2022 at 1:30 p.m. ET.

A live webcast of the panel can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.

About Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib (SNDX-5613), a highly selective inhibitor of the Menin–MLL binding interaction, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, both currently in pivotal trials. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn.

Syndax Contacts

Investor Contact
Melissa Forst
Argot Partners
melissa@argotpartners.com 
Tel 212.600.1902

Media Contact
Benjamin Kolinski
benjamin.kolinski@gcihealth.com 
Tel 862.368.4464

SNDX-G

 

View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-citis-biopharma-virtual-co-panel-day-301544712.html

SOURCE Syndax Pharmaceuticals, Inc.

FAQ

What is the date of Syndax Pharmaceuticals' panel discussion at Citi's Biopharma Virtual Co-Panel Day?

The panel discussion will take place on May 18, 2022.

Who is participating in the oncology panel discussion for Syndax Pharmaceuticals?

Michael A. Metzger, the CEO of Syndax Pharmaceuticals, will participate.

What are the key products being discussed by Syndax Pharmaceuticals?

Syndax is highlighting revumenib and axatilimab, which are currently in pivotal trials.

How can I access the webcast for Syndax Pharmaceuticals' panel discussion?

The live webcast can be accessed from the Investor section of Syndax's website.

What time is Syndax Pharmaceuticals' panel discussion scheduled?

The panel is scheduled for 1:30 p.m. ET.